Ascletis executes HKD 1.93 million on-market share buyback; outstanding share count steady at 1.07 billion

Bulletin Express

Jun 26

Ascletis Pharma Inc. disclosed that on 26 June 2026 it repurchased 200,000 ordinary shares on the Hong Kong Stock Exchange, paying between HKD 9.38 and HKD 9.94 per share for an aggregate consideration of HKD 1.93 million. The shares are earmarked for cancellation.

The transaction was conducted under the repurchase mandate granted on 22 May 2025, which authorises the company to buy back up to 96.28 million shares. Including the latest purchase, Ascletis has repurchased 9.89 million shares—about 1.03 % of the issued share base at the time the mandate was approved.

Issued share capital remains unchanged. As at the close of 26 June 2026, Ascletis had 1.06 billion issued shares (excluding 7.08 million treasury shares), with total shares outstanding at 1.07 billion. The 30-day moratorium on new share issues following the buyback extends to 26 July 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1166854719"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1166854719\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1166854719?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-26 18:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1166854719","market":"hk","top_or_hot":-1,"title":"Ascletis executes HKD 1.93 million on-market share buyback; outstanding share count steady at 1.07 billion","media":"Bulletin Express","content":"<p>Ascletis Pharma Inc. disclosed that on 26 June 2026 it repurchased 200,000 ordinary shares on the Hong Kong Stock Exchange, paying between HKD 9.38 and HKD 9.94 per share for an aggregate consideration of HKD 1.93 million. The shares are earmarked for cancellation.</p>\n<p>The transaction was conducted under the repurchase mandate granted on 22 May 2025, which authorises the company to buy back up to 96.28 million shares. Including the latest purchase, Ascletis has repurchased 9.89 million shares—about 1.03 % of the issued share base at the time the mandate was approved.</p>\n<p>Issued share capital remains unchanged. As at the close of 26 June 2026, Ascletis had 1.06 billion issued shares (excluding 7.08 million treasury shares), with total shares outstanding at 1.07 billion. The 30-day moratorium on new share issues following the buyback extends to 26 July 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascletis executes HKD 1.93 million on-market share buyback; outstanding share count steady at 1.07 billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscletis executes HKD 1.93 million on-market share buyback; outstanding share count steady at 1.07 billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-26 18:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ascletis Pharma Inc. disclosed that on 26 June 2026 it repurchased 200,000 ordinary shares on the Hong Kong Stock Exchange, paying between HKD 9.38 and HKD 9.94 per share for an aggregate consideration of HKD 1.93 million. The shares are earmarked for cancellation.</p>\n<p>The transaction was conducted under the repurchase mandate granted on 22 May 2025, which authorises the company to buy back up to 96.28 million shares. Including the latest purchase, Ascletis has repurchased 9.89 million shares—about 1.03 % of the issued share base at the time the mandate was approved.</p>\n<p>Issued share capital remains unchanged. As at the close of 26 June 2026, Ascletis had 1.06 billion issued shares (excluding 7.08 million treasury shares), with total shares outstanding at 1.07 billion. The 30-day moratorium on new share issues following the buyback extends to 26 July 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01672","symbol_name":"歌礼制药-B","start_time":0,"source_url":"","article_id":"1166854719","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1166854719","pubTimestamp":1782469503,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Ascletis Pharma Inc. disclosed that on 26 June 2026 it repurchased 200,000 ordinary shares on the Hong Kong Stock Exchange, paying between HKD 9.38 and HKD 9.94 per share for an aggregate...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01672":"歌礼制药-B"},"translate_title":"歌礼执行193万港元场内股份回购；流通股数量稳定在10.7亿股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":1},"content_text":"Ascletis Pharma Inc. disclosed that on 26 June 2026 it repurchased 200,000 ordinary shares on the Hong Kong Stock Exchange, paying between HKD 9.38 and HKD 9.94 per share for an aggregate consideration of HKD 1.93 million. The shares are earmarked for cancellation.\nThe transaction was conducted under the repurchase mandate granted on 22 May 2025, which authorises the company to buy back up to 96.28 million shares. Including the latest purchase, Ascletis has repurchased 9.89 million shares—about 1.03 % of the issued share base at the time the mandate was approved.\nIssued share capital remains unchanged. As at the close of 26 June 2026, Ascletis had 1.06 billion issued shares (excluding 7.08 million treasury shares), with total shares outstanding at 1.07 billion. The 30-day moratorium on new share issues following the buyback extends to 26 July 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}